Working Group: Topics
Completed Topics
Topic: Genomic Tests for Ovarian Cancer Detection and Management
EGAPP Recommendation: Pending
Summary Article: Pending
Evidence Report: Genomic Tests for Ovarian Cancer Detection and Management, Duke University Evidence-based Practice Center
Supplementary Evidence Report: Pending
Other products: Pending
Key Questions:
-
Question 1: What is the evidence that ovarian cancer genomic tests performed in a typical clinical laboratory actually measure what they are purported to measure?
-
Question 2: What is the sensitivity and specificity of genomic tests in detecting ovarian cancer in asymptomatic and symptomatic women, including high-risk women?
-
Question 3: What is the evidence that genomic testing to detect ovarian cancer in asymptomatic women, including high-risk women, changes clinical management and leads to improved clinical outcomes?
-
Question 4: What is the evidence that genomic testing in women with clinical suspicionof ovarian cancer or with already-diagnosed ovarian cancer changes clinical management and leads to improved health outcomes?
-
Question 5: What are the harms of using genomic tests for ovarian cancer prevention and management?
-
Question 6: Has direct-to-consumer and direct-to-physician marketing of genomic tests
for ovarian cancer increased the “appropriate” use of these tests?
Why EGAPP Selected this topic for Review:
Key criteria: Critical need for reliable early detection due to high case fatality rate of ovarian cancer.
Other Considerations: Collaboration with CDC Division of Cancer Prevention and Control; promotion of new proteomic screening tests when the report was commissioned.
Page last updated: May 15, 2013
Page last reviewed: December 23, 2008
Content Source: OPHG Staff